<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Liposomal-encapsulated <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase was clinically applied to patient showing an increase in neutrophil active oxygen generation, and those with diseases such as severe <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA), <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and progressive systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (<z:chebi fb="17" ids="53277">PSS</z:chebi>) in which presence of a plasmatic clastogenic factor has been demonstrated </plain></SENT>
<SENT sid="1" pm="."><plain>Liposomal SOD injection (2.5 mg twice a week) resulted in marked remission in 12 out of 16 patients with active <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The drug was impressively effective on patients with intestinal <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Remission rates in the other diseases was 7 out of 8 mucocutaneous lymphnode syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCLS</z:e>, <z:e sem="disease" ids="C0026691" disease_type="Disease or Syndrome" abbrv="MLNS|MCLS">Kawasaki disease</z:e>) 3 out of 5 <z:hpo ids='HP_0000964'>dermatitis</z:hpo> herpetiformis, IgA linear <z:e sem="disease" ids="C0085932" disease_type="Disease or Syndrome" abbrv="">bullous dermatosis</z:e> or severe cement <z:hpo ids='HP_0000964'>dermatitis</z:hpo>, 4 out of 9 active and severe RA, 3 out of 3 PSS, 4 out of 4 <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo>, 3 out of 4 <z:hpo ids='HP_0100279'>colitis ulcerosa</z:hpo>, and 2 out of 2 unresponsive (hemolytic) <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>To be emphasized was that three severe active RA patients and two terminal-stage <z:chebi fb="17" ids="53277">PSS</z:chebi> patients with <z:hpo ids='HP_0002094'>dyspnea</z:hpo> due to <z:mp ids='MP_0006050'>lung fibrosis</z:mp> showed dramatic improvement after administration of liposomal SOD </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, in 13 out of 15 malignant neo plastic patients including <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and leucemia who were receiving radiotherapy (total dose, more than 4000 rads) and chemotherapy including <z:chebi fb="0" ids="48120">anthracycline</z:chebi> analogs (total over 450 mg/m2) and <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, the drug also prevented the appearance of myocardiac injury and <z:mp ids='MP_0003045'>fibrosis</z:mp>, sometimes seen as a consequence of chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>Liposomal SOD, which shows no toxicity, has various advantages compared to free SOD preparations, and is highly and broadly applicable to various clinical disorders </plain></SENT>
</text></document>